Patent

Delhi High Court grants interim injunction to Novartis against Natco’s use of Revolade patent 

by
1 Comment

The Delhi High Court recently granted an interlocutory injunction to Novartis against Natco’s use of Eltrombopag Olamine (EO). The debate at the crux of the dispute is, or rather was, the dichotomy between deference to the validity of a granted patent vis-a-vis the challenge to its validity and consequently disregarding the exclusivity granted to it, in litigation. The court in the present matter seemed to have sided with the former and placed the ‘presumption’ of validity of a patent at…


Read More »
Others

Delhi High Court extends the deadline to submit comments on Delhi High Court Intellectual Property Rights Division Rules, 2021

by
Leave a Comment

The Delhi High Court Registry on October 26, 2021 announced an extension for submitting suggestions and comments on the proposed Delhi High Court Intellectual Property Rights Division Rules, 2021. As per this, the new deadline stands as November 10, 2021.  The proposed rules come out as a result of the Tribunal Reforms Act, 2021, and the recommendations made by the committee constituted by the Chief Justice of the Delhi High Court Justice D. N Patel, to further the implementation of…


Read More »
Patent

Division Bench Stays the Interim Injunction Granted to Kibow Biotech, calls Methodology of the Single Judge Bench for Establishing Prima Facie case “Flawed”

by
Leave a Comment

The present post discusses another instance of interim injunctions imposed by our courts on the basis of problematic rationale. Sometime back, I reported on an interim injunction order by a Single Judge Bench of Madras High Court against La Renon Healthcare Pvt. Ltd. and Stanford Labs Pvt. Ltd (the defendants). Without narrating the background in detail again, the order was passed in an ongoing patent infringement dispute (covered here and here for the blog) surrounding Plaintiff no. 2’s (Kibow Biotech)…


Read More »
Patent

Ensuring Access to TB drugs: Is Compulsory License the Way?

by
Leave a Comment

This Post has been co-authored by Rahul Bajaj and Praharsh Gour. Rahul is presently working as a Senior Resident Fellow, Partnerships at Vidhi. Before his stint with Vidhi, Rahul has worked as a law clerk for Justice D. Y Chandrachud (2020-21) and is a Rhodes Scholar (2018). He has also blogged for us in the past and was the SpicyIP Fellow for 2016. Readers can access posts by Rahul here.  [Note: Long post ahead] Ensuring Access to TB drugs: Is…


Read More »
Copyright Design Geographical Indication Patent Plant Variety Protection Trademark

Back from the Dead? Parliamentary Committee on IP suggests against scrapping of IPAB

by
4 Comments

One may recall the scene in Macbeth where he encounters the ghost of his former friend Banquo and exclaims in disbelief. I am sure many would have exclaimed with similar sentiment after reading the suggestions of the recent Parliamentary Standing Committee Report on Review of IPR regime in India, which suggests re-institution of IPAB. At the outset, let me clarify, I am in no way against the idea of having a dedicated IP court, which will ensure timely disposal of…


Read More »
Patent

Fear Won’t Take You Anywhere: Delhi HC Revisits Bolar Exception, Rules Apprehensions Cannot Deny Liberty under Section 107A

by
Leave a Comment

The Delhi High Court in an order dated 20th July, 2021 vacated an ex-parte interim injunction (pdf), allowing the SMS Pharmaceuticals to export Merck’s patented anti-diabetic drug ‘Sitagliptin’ for R&D purposes on the condition that it files an affidavit mentioning the quantities of the drug exported and undertaking that the export is only for the above said purpose. While coming to this understanding, the court relied extensively on the Single Judge’s and Division Bench’s decisions in Bayer v. Union of…


Read More »
COVID-19 Data Exclusivity Patent Trade Secret

Compulsion for Compulsory Licenses for Covid Vaccines Climbs: But Are They the Cure?

by
Leave a Comment

On 11th May, it was reported that Kerala High Court has sought a response from the Central government on a PIL seeking direction to the government to invoke the compulsory license (CL) provisions for the COVID-19 vaccines. In the PIL, the Petitioner (Adv. Gopakumar GV) argues that in the present crisis resorting to CL will assist the nation to ramp up the quantity of vaccine output and thus overcome its scarcity. As reported before, the government is already facing a…


Read More »
COVID-19 Patent

Centre Sees No Compulsion to Issue Compulsory Licenses for Covid Drugs

by
1 Comment

May 2021 has been an interesting month so far for compulsory licenses. First the Supreme Court inquired about the Government’s position on issuing CLs for COVID-19 related drugs and vaccines, then Natco filed an application requesting a compulsory license for Baricitinib. This is followed by Delhi HC’s interim order, where it too hinted that the Central government could explore the alternative of compulsory licensing. Even on the international front, one of the major opponents of the compulsory license mechanism- the…


Read More »
COVID-19 Patent

A Recipe for Disaster: Export Bans, TRIPS Waiver and Hyper Nationalism

by
Leave a Comment

(Long post ahead) On 23rd April, Ned Price, a spokesperson for the US State Department, revealed that the Biden administration is not considering lifting the export bans on the necessary raw materials for the COVID-19 vaccine. This refusal comes in response to the requests (see here and here) made by the SII CEO Adar Poonawalla to get rid of the export bans and assist in ramping up the outputs of vaccines in the global market. (Side note:  Back in Feb,…


Read More »
COVID-19 Drug Regulation Patent

Indian Govt. Permits Manufacture of Covaxin by Haffkine Institute – But Why Not Others Too?

by
2 Comments

(This post has been co-authored with Swaraj Barooah) In what seems like a  whiff of good news amidst the debacle surrounding availability of  COVID-19 vaccine in India, the Central Government has permitted the Haffkine Institute to manufacture Covaxin, on  a “technology transfer” basis, for a period of one year. This is definitely needed and hopefully will address the vaccine shortage in the country to some extent. But does this mean that the Central Government had the IP and technology transfer…


Read More »
  1. Pages:
  2. 1
  3. 2
  4. 3